<SEC-DOCUMENT>0001299130-23-000093.txt : 20230802
<SEC-HEADER>0001299130-23-000093.hdr.sgml : 20230802
<ACCEPTANCE-DATETIME>20230802161052
ACCESSION NUMBER:		0001299130-23-000093
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230802
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230802
DATE AS OF CHANGE:		20230802

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
		CENTRAL INDEX KEY:			0001299130
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				161590339
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34899
		FILM NUMBER:		231135652

	BUSINESS ADDRESS:	
		STREET 1:		1305 O'BRIEN DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		650-521-8000

	MAIL ADDRESS:	
		STREET 1:		1305 O'BRIEN DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PACIFIC BIOSCIENCES OF CALIFORNIA INC
		DATE OF NAME CHANGE:	20050829

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NANOFLUIDICS INC
		DATE OF NAME CHANGE:	20040729
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>pacb-20230802.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:21c8f849-4733-4e48-9f95-0792ce893515,g:042e2ed6-378d-4041-85fa-b761f8270455,d:53f3bb8bb1524ebdbe20ea81e61b1998--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>pacb-20230802</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0001299130</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-22">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="pacb-20230802.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-02</xbrli:startDate><xbrli:endDate>2023-08-02</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i53f3bb8bb1524ebdbe20ea81e61b1998_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:0.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Securities Exchange Act of 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">August&#160;2, 2023</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Pacific Biosciences of California, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-34899</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">16-1590339</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(IRS Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">1305 O&#8217;Brien Drive</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Menlo Park</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">94025</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices) (Zip Code)</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">521-8000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code) </span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report) </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-13">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">PACB</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The NASDAQ Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">o</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i53f3bb8bb1524ebdbe20ea81e61b1998_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.02.&#160;&#160;&#160;&#160;RESULTS OF OPERATIONS AND FINANCIAL CONDITION.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;2, 2023, Pacific Biosciences of California, Inc. (the &#8220;Company&#8221;) announced its financial results for its second fiscal quarter ended June&#160;30, 2023. A copy of the press release containing the announcement is attached as Exhibit 99.1 hereto and is incorporated herein by reference.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information furnished in this Item 2.02 and Exhibit 99.1 attached hereto shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></div><div id="i53f3bb8bb1524ebdbe20ea81e61b1998_64"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.02.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2023, the Company entered into an agreement and plan of reorganization (the &#8220;Merger Agreement&#8221;), pursuant to which the Company will acquire Apton Biosystems, Inc., a privately held genomics company (&#8220;Apton&#8221;). </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the Merger Agreement, upon the closing of the acquisition, the Company will, among other things, issue to holders of Apton&#8217;s outstanding equity interests (&#8220;Apton Securityholders&#8221;) up to approximately 6.3 million shares of the Company&#8217;s common stock, par value $0.001 per share (&#8220;Common Stock&#8221;). Additionally, subject to the terms and conditions of the Merger Agreement and the achievement of a specified milestone, Apton Securityholders will also be entitled to receive $25 million, which the Company may elect to pay in cash, shares of Common Stock or a combination of cash and shares of Common Stock. At this time, the number of shares, if any, to be issued in connection with the achievement of the specified milestone is not known, and will be calculated based on the daily volume-weighted average price of the Common Stock for the twenty trading days ending on and including the fifth trading day immediately prior to the occurrence of the specified milestone. Under the terms of the Merger Agreement, the Company may pay cash in lieu of Common Stock to ensure that the issuance of Common Stock as contemplated by the Merger Agreement does not exceed 19.9% of the shares of Common Stock then outstanding. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the shares of Common Stock issued or issuable pursuant to the Merger Agreement have been issued, or will be issued, in reliance upon the exemptions from registration afforded by Section 4(a)(2) of the Securities Act and Rule 506 thereunder. Such issuances and sales are not being conducted in connection with a public offering, and no public solicitation or advertisement will be made or relied upon in connection therewith.</span></div><div id="i53f3bb8bb1524ebdbe20ea81e61b1998_71"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7.01.&#160;&#160;&#160;&#160;REGULATION FD DISCLOSURE.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2023, the Company issued a press release relating to its acquisition of Apton, a copy of which is furnished herewith as Exhibit 99.2 and incorporated herein by reference.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally on August 2, 2023, the Company issued a press release announcing the commencement of customer shipments of Onso short-read sequencing instruments, a copy of which is furnished herewith as Exhibit 99.3 and incorporated herein by reference.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information furnished in this Item 7.01 and Exhibits 99.2 and 99.3 attached hereto shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></div><div id="i53f3bb8bb1524ebdbe20ea81e61b1998_10"></div><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9.01.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND EXHIBITS.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibits.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit991-earningsrelease.htm">Press Release dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit991-earningsrelease.htm">August</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit991-earningsrelease.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit991-earningsrelease.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit991-earningsrelease.htm">, 2023, titled &#8220;PacBio Announces Second Quarter 2023 Financial Results&#8221; (furnished and not filed herewith solely pursuant to Item 2.02).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit992-pressreleasex08.htm">Press Release dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit992-pressreleasex08.htm">August 2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit992-pressreleasex08.htm">, 2023, titled &#8220;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit992-pressreleasex08.htm">PacBio </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit992-pressreleasex08.htm">Enters into Agreement to Acquire</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit992-pressreleasex08.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit992-pressreleasex08.htm">Apton Biosystems to Accelerate the Development of a Next Generation, High Throughput, Short-read Sequencer</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit992-pressreleasex08.htm">&#8221; (furnished and not filed herewith solely pursuant to Item 7.01).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit993-pressreleasex08.htm">Press Release dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit993-pressreleasex08.htm">August 2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit993-pressreleasex08.htm">, 2023, titled &#8220;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit993-pressreleasex08.htm">PacBio </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit993-pressreleasex08.htm">Begins Commercialization of the</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit993-pressreleasex08.htm"> Onso Short</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit993-pressreleasex08.htm">-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit993-pressreleasex08.htm">Read</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit993-pressreleasex08.htm"> Sequencing System</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit993-pressreleasex08.htm">&#8221; (furnished and not filed herewith solely pursuant to Item </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit993-pressreleasex08.htm">7.01</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit993-pressreleasex08.htm">).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i53f3bb8bb1524ebdbe20ea81e61b1998_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pacific Biosciences of California, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Michele Farmer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Michele Farmer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Vice President and Chief Accounting Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: August&#160;2, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991-earningsrelease.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i73f69c1b80cc46c496807bbb3b64fd39_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PacBio Announces Second Quarter 2023 Financial Results</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Menlo Park, Calif. </font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211; August&#160;2, 2023 &#8211; PacBio (NASDAQ&#58; PACB) today announced financial results for the quarter ended June 30, 2023.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Second quarter results</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Revenue of $47.6 million, a 34% increase compared with $35.5 million in the prior-year period.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Recognized revenue on 47 sequencing systems in the second quarter, including 45 Revio systems and 2 Sequel IIe systems, compared to 36 Sequel II&#47;IIe systems in the prior-year period.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Instrument revenue of $29.9 million compared with $15.6 million in the prior-year period. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Consumables revenue of $13.7 million compared with $14.6 million in the prior-year period.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Service and other revenue of $3.9 million compared with $5.3 million in the prior-year period.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit for the second quarter of 2023 was $15.5 million, representing a 4% decrease compared with $16.2 million for the second quarter of 2022 and a gross margin of 33% in the second quarter of 2023 compared to 46% for the second quarter of 2022. Non-GAAP gross profit for the second quarter of 2023 was $15.7 million and represented a non-GAAP gross margin of 33% in the second quarter of 2023, compared to a non-GAAP gross profit of $16.4 million in the second quarter of 2022 which represented a non-GAAP gross margin of 46% (see accompanying tables for reconciliations of GAAP and non-GAAP measures). </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses totaled $88.7 million for the second quarter of 2023, compared to $84.2 million for the second quarter of 2022. Non-GAAP operating expenses totaled $86.7 million for the second quarter of 2023, compared to $89.6 million for the second quarter of 2022. Operating expenses for the second quarter of 2023 and the second quarter of 2022 included non-cash share-based compensation of $16.7 million and $18.0 million, respectively.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss for the second quarter of 2023 was $69.8 million, compared to a net loss of $71.4 million for the second quarter of 2022. Non-GAAP net loss was $65.6 million for the second quarter of 2023, compared to $76.6 million for the second quarter of 2022. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share for the second quarter of 2023 was $0.28 compared to net loss per share of $0.32 for the second quarter of 2022. Non-GAAP net loss per share for the second quarter of 2023 was $0.26 compared to $0.34 for the second quarter of 2022.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and investments, excluding short- and long-term restricted cash, at June&#160;30, 2023, totaled $829.9 million, compared to $772.3 million at December&#160;31, 2022.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Updates since our last earnings release</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Commenced shipping of the Onso platform, an innovative benchtop short-read DNA sequencing system that provides users with an extraordinary level of accuracy using PacBio's proprietary sequencing by binding (SBB) technology. PacBio expects to complete the installation of the first Onso instrument and ship related consumables later this month. The milestone payment associated with PacBio's acquisition of Omniome will be triggered once both the Onso instrument and related consumables have been shipped. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Entered into an agreement to acquire Apton Biosystems, Inc. (Apton), a private company developing a high-throughput short-read sequencer.  PacBio plans to integrate SBB chemistry with Apton's advanced optics and imaging technologies to accelerate our development of a highly accurate, high throughput, short-read sequencer.  </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Announced that Bioscientia, a leading global provider of clinical laboratory testing services for diagnostics based in Germany, implemented Revio to sequence several thousand human genomes per year.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Collaborated with Radboud University Medical Center (Radboudumc), one of Europe's largest academic centers for human genetics, to explore genetic causes of rare and genetic diseases. Radboudumc plans to study the potential clinical utility and better understand the health economics of bringing highly accurate HiFi sequencing in a clinical setting on a large scale.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Appointed Olga Troyanskaya, Ph.D., Professor of Computer Science and the Lewis Sigler Institute for Integrative Genomics at Princeton University to PacBio&#8217;s Scientific Advisory Board (SAB) and Jay Shendure, Ph.D., Professor of Genome Sciences at the University of Washington, as Chair. SAB provides guidance to the research and development efforts at PacBio, including critical feedback, advice, and expertise on future technological and scientific direction to inform PacBio&#8217;s priorities and roadmaps for current and future products. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">Issued $441 million principal amount of 1.375% Convertible Senior Notes due 2030 in exchange for $441 million principal amount of 1.50% Convertible Senior Notes due 2028 (2028 Notes) in a privately negotiated exchange deal with a holder of PacBio&#8217;s 2028 Notes.</font></div><div style="margin-top:6pt"><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#34;PacBio continued to gain momentum in the second quarter as Revio demand drove record quarterly revenue,&#34; said Christian Henry, President and Chief Executive Officer. &#34;The team continues to execute on scaling manufacturing and delivering the new product to customers, and we're seeing customers ramp sequencing on Revio. I'm also pleased to share that we've commenced shipment of Onso today, our highly differentiated short-read benchtop sequencer developed as a result of our acquisition of Omniome in 2021. I'm also excited to announce that we entered into an agreement to acquire Apton, enabling us to accelerate the development of a high-throughput instrument capable of sequencing billions of reads per flow cell.&#34;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quarterly Conference Call Information </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management will host a quarterly conference call to discuss its second quarter ended June&#160;30, 2023, results today at 5&#58;00 p.m. Eastern Time. Investors may listen to the call by dialing 1-888-349-0136, if outside the U.S., by dialing 1-412-317-0459, requesting to join the &#8220;PacBio Q2 Earnings Call&#34;. The call will be webcast live and available for replay at PacBio's website at https&#58;&#47;&#47;investor.pacificbiosciences.com.  </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About PacBio</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacific Biosciences of California, Inc. (NASDAQ&#58; PACB) is a premier life science technology company that is designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include our existing HiFi long-read sequencing technology and our emerging short-read Sequencing by Binding (SBB</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) technology. Our products address solutions across a broad set of applications, including human genomics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow &#64;PacBio.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PacBio products are provided for research use only. Not for use in diagnostic procedures.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statement regarding use of non&#8208;GAAP financial measures </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reports non&#8208;GAAP results for basic and diluted net income and loss per share, net income, net loss, gross margins, gross profit and operating expenses in addition to, and not as a substitute for, or because it believes that such information is superior to, financial measures calculated in accordance with GAAP.  The Company believes that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of the Company&#8217;s non-GAAP financial measures as tools for comparison.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's financial measures under GAAP include substantial charges that are listed in the itemized reconciliations between GAAP and non&#8208;GAAP financial measures included in this press release. The amortization of acquired intangible assets excluded from GAAP financial measures relates to acquired intangible assets that were recorded as part of the purchase accounting during the year ended December 31, 2021. Such intangible assets contribute to revenue generation and its amortization will recur in future periods until they are fully amortized. Management has excluded the effects of these items in non&#8208;GAAP measures to assist investors in analyzing and assessing past and future operating performance. In addition, management uses non-GAAP measures to compare the Company&#8217;s performance relative to forecasts and strategic plans and to benchmark its performance externally against competitors. </font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non&#8208;GAAP information and the reconciliation between these presentations, to more fully understand its business. A reconciliation of the Company&#8217;s non-GAAP financial measures to their most directly comparable financial measure stated in accordance with GAAP has been provided in the financial statement tables included in this press release. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This press release contains &#8220;forward-looking statements&#8221; within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the availability, uses, accuracy, coverage, advantages, quality or performance of, or benefits or expected benefits of using, PacBio products or technologies&#59; PacBio's acquisition of Apton, including the potential benefits of adding short-read, high-throughput sequencing technologies to PacBio's product portfolio and the synergies such technologies may provide with PacBio's existing offerings&#59; expectations with respect to customer demand for our products and technologies and growth in our business&#59; and the impact of new products, including the Revio, Onso and Apton systems. Reported results and orders for the Revio and Onso systems should not be considered an indication of future performance. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including, challenges inherent in developing, manufacturing, launching, marketing and selling new products, and achieving anticipated new sales, including the Onso system&#59; potential cancellation of existing instrument orders&#59; assumptions, risks and uncertainties related to the ability to attract new customers and retain and grow sales from existing customers&#59; risks related to our acquisition of Apton and our ability to successfully execute on such acquisition, such as the failure to successfully integrate Apton or to otherwise realize the anticipated benefits of the Apton acquisition&#59; the impact of U.S. export restrictions on the shipment of PacBio products to certain countries&#59; rapidly changing technologies and extensive competition in genomic sequencing&#59; unanticipated increases in costs or expenses&#59; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products and products under development&#59; potential product performance and quality issues and potential delays in development timelines&#59; the possible loss of key employees, customers, or suppliers&#59; customers and prospective customers curtailing or suspending activities using our products&#59; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights&#59; and other risks associated with macroeconomic conditions such as uncertain capital markets, pandemic-related lockdowns, heightened inflation, war in Europe&#59;  and risks associated with international operations, among others. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption &#8220;Risk Factors.&#8221; These forward-looking statements are based on current expectations and speak only as of the date hereof&#59; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements that follow should be read in conjunction with the notes set forth in PacBio's Quarterly Report on Form 10-Q when filed with the Securities and Exchange Commission. </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contacts</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investors&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Todd Friedman</font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">650.521.8450</font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ir&#64;pacb.com</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Media&#58;</font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lizelda Lopez</font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pr&#64;pacb.com</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i73f69c1b80cc46c496807bbb3b64fd39_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pacific Biosciences of California, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Condensed Consolidated Statement of Operations</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands, except per share amounts)</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.478%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt 0 7pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Three Months Ended</font></td></tr><tr><td colspan="3" style="padding:0 1pt 0 7pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">June 30, 2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">March 31, 2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">June 30, 2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Revenue&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Product revenue </font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">43,655&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">34,654&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">30,175&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Service and other revenue </font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3,918&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4,246&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5,292&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Total revenue </font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">47,573&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">38,900&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">35,467&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cost of Revenue&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cost of product revenue </font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">28,432&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">25,164&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15,499&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cost of service and other revenue </font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3,412&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3,792&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3,592&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortization of intangible assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">183&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">183&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">183&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Total cost of revenue </font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">32,027&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">29,139&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">19,274&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 67pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Gross profit </font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15,546&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9,761&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">16,193&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Operating Expense&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Research and development </font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">46,173&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">48,939&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">50,348&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Sales, general and administrative </font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">40,573&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">39,818&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">39,252&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Change in fair value of contingent consideration </font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,975&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">12,256&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(5,438)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Total operating expense </font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">88,721&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">101,013&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">84,162&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Operating loss </font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(73,175)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(91,252)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(67,969)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Loss on extinguishment of debt </font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2,033)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Interest expense </font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(3,554)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(3,630)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(3,681)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other income, net </font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">8,929&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6,867&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">256&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Loss before expense (benefit) from income taxes</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(69,833)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(88,015)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(71,394)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Expense (benefit) from income taxes</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(69,833)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(88,015)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(71,394)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net loss per share&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Basic </font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(0.28)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(0.36)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(0.32)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Diluted </font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(0.28)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(0.36)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(0.32)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Weighted average shares outstanding used in calculating net loss per share&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Basic </font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">250,070&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">242,032</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">224,499&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Diluted </font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">250,070&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">242,032</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">224,499&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.5pt">Change in fair value of contingent consideration during the three months ended June 30, 2023, March&#160;31, 2023, and June&#160;30, 2022 was due to fair value adjustments of milestone payments payable upon the commercialization of acquired IPR&#38;D</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.5pt">Loss on extinguishment of debt during the three months ended June 30, 2023 is related to the exchange of a portion of the Company's 1.50% Convertible Senior Notes due 2028 for the Company's 1.375% Convertible Senior Notes due 2030. </font></div><div style="margin-top:6pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-right:-9pt;text-align:center"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pacific Biosciences of California, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Condensed Consolidated Statement of Operations</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands, except per share amounts)</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt 0 7pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Three Months Ended</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Six Months Ended</font></td></tr><tr><td colspan="3" style="padding:0 1pt 0 7pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">June 30, 2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">June 30, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">June 30, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">June 30, 2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Revenue&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Product revenue </font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">43,655&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">30,175&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">78,309&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">58,419&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Service and other revenue </font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3,918&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5,292&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">8,164&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10,221&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Total revenue </font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">47,573&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">35,467&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">86,473&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">68,640&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cost of Revenue&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cost of product revenue </font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">28,432&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15,499&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">53,596&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">30,319&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cost of service and other revenue </font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3,412&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3,592&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">7,204&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">7,607&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortization of intangible assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">183&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">183&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">366&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">366&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Total cost of revenue </font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">32,027&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">19,274&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">61,166&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">38,292&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 67pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Gross profit </font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15,546&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">16,193&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">25,307&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">30,348&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Operating Expense&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Research and development </font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">46,173&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">50,348&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">95,112&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">103,285&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Sales, general and administrative </font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">40,573&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">39,252&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">80,391&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">79,056&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Change in fair value of contingent consideration </font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,975&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(5,438)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">14,231&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(6,501)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Total operating expense </font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">88,721&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">84,162&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">189,734&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">175,840&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Operating loss </font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(73,175)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(67,969)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(164,427)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(145,492)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Loss on extinguishment of debt </font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2,033)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2,033)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Interest expense </font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(3,554)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(3,681)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(7,184)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(7,378)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other income (expense), net </font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">8,929&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">256&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15,796&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(23)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Loss before expense (benefit) from income taxes</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(69,833)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(71,394)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(157,848)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(152,893)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Expense (benefit) from income taxes</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(69,833)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(71,394)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(157,848)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(152,893)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net loss per share&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Basic </font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(0.28)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(0.32)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(0.64)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(0.68)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Diluted </font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(0.28)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(0.32)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(0.64)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(0.68)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Weighted average shares outstanding used in calculating net loss per share&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Basic </font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">250,070&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">224,499&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">246,074&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">223,400&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Diluted </font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">250,070&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">224,499&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">246,074&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">223,400&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.5pt">Change in fair value of contingent consideration during the three and six months ended June&#160;30, 2023 and 2022  was due to fair value adjustments of milestone payments payable upon the commercialization of acquired IPR&#38;D</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.5pt">Loss on extinguishment of debt during the three and six months ended June&#160;30, 2023 is related to the exchange of a portion of the Company's 1.50% Convertible Senior Notes due 2028 for the Company's 1.375% Convertible Senior Notes due 2030. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i73f69c1b80cc46c496807bbb3b64fd39_10"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pacific Biosciences of California, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Condensed Consolidated Balance Sheets</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands)</font><font style="font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30,<br>2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,<br>2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and investments</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">829,862&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">772,318&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,034&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,786&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">67,608&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,381&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepaid and other current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,748&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,289&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property and equipment, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40,317&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,580&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease right-of-use assets, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,444&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39,763&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restricted cash</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,722&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,222&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangible assets, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">409,779&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">410,245&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">409,974&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">409,974&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other long-term assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,143&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,528&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,847,631&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,767,086&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liabilities and Stockholders' Equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts payable</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,512&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,028&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,010&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32,596&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred revenue</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,975&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32,292&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45,842&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49,956&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contingent consideration liability</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">186,325&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">172,094&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Convertible senior notes, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">891,795&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">896,683&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,173&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,533&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stockholders' equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">641,999&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">562,904&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Liabilities and Stockholders' Equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,847,631&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,767,086&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i73f69c1b80cc46c496807bbb3b64fd39_13"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pacific Biosciences of California, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of Non-GAAP Financial Measures</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands, except per share amounts)</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt 0 7pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Three Months Ended</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Six Months Ended</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">June 30,<br>2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">March 31,<br>2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">June 30,<br>2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">June 30,<br>2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">June 30,<br>2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">GAAP net loss</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(69,833)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(88,015)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(71,394)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(157,848)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(152,893)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Change in fair value of contingent consideration</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,975&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">12,256&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(5,438)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">14,231&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(6,501)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Loss on extinguishment of debt</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"> (2)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2,033&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2,033&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">228&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">228&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">228&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">456&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">457&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Non-GAAP net loss </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(65,597)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(75,531)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(76,604)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(141,128)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(158,937)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">GAAP net loss per share</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(0.28)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(0.36)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(0.32)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(0.64)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(0.68)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Change in fair value of contingent consideration</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">0.01&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">0.05&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(0.02)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">0.06&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(0.03)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Loss on extinguishment of debt</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"> (2)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">0.01&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">0.01&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Non-GAAP net loss per share </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(0.26)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(0.31)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(0.34)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(0.57)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(0.71)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">GAAP gross profit</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15,546&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9,761&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">16,193&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">25,307&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">30,348&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">183&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">183&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">183&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">366&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">366&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Non-GAAP gross profit</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">15,729&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9,944&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">16,376&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">25,673&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">30,714&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">GAAP gross profit %</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">33%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">25%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">46%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">29%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">44%</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Non-GAAP gross profit %</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">33%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">26%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">46%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">30%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">45%</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">GAAP total operating expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">88,721&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">101,013&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">84,162&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">189,734&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">175,840&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Change in fair value of contingent consideration</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1,975)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(12,256)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5,438&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(14,231)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6,501&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(45)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(45)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(45)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(90)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(91)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Non-GAAP total operating expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">86,701&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">88,712&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">89,555&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">175,413&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:400;line-height:120%">182,250&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.5pt">Change in fair value of contingent consideration was related to fair value adjustments of milestone payments payable upon the commercialization of acquired IPR&#38;D.</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.5pt">Loss on extinguishment of debt during the three and six months ended June&#160;30, 2023 is related to the exchange of a portion of the Company's 1.50% Convertible Senior Notes due 2028 for the Company's 1.375% Convertible Senior Notes due 2030. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>exhibit992-pressreleasex08.htm
<DESCRIPTION>EX-99.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i9cae881f28c3441bac86947313518820_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PacBio Enters into Agreement to Acquire Apton Biosystems to Accelerate the Development of a Next Generation, High Throughput, Short-read Sequencer</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PacBio will combine Apton&#8217;s proprietary sequencing technology with its highly accurate Sequencing by Binding chemistry to develop a high-throughput sequencer designed to deliver billions of reads per flow cell</font></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MENLO PARK, Calif., August 2, 2023 &#47;PRNewswire&#47; -- PacBio, a leading developer of high-quality, highly accurate sequencing solutions, today announced that it has entered into an agreement to acquire Apton Biosystems, Inc (Apton), a Bay-Area-based company developing a high throughput short-read sequencer using state-of-the-art optics and image processing, paired with novel clustering and chemistry, that is designed to enable the sequencing of billions of clusters of DNA on one flow cell. As a combined organization, PacBio plans to integrate its Sequencing by Binding (SBB&#8482;) short-read chemistry into Apton&#8217;s high throughput instrument to offer a differentiated high throughput sequencer.   </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;I am impressed with Apton&#8217;s progress in developing a novel, high throughput sequencing platform that has the potential to deliver very low-cost sequencing at tremendous scale. By integrating our highly accurate SBB technology with Apton&#8217;s advanced optics and image processing capabilities, PacBio expects to commercialize a high throughput short-read platform faster than we had planned,&#8221; said Christian Henry, President and CEO of PacBio.  &#8220;This acquisition is consistent with our strategy to develop a multiproduct short-read sequencing portfolio alongside our long-read sequencing platforms, giving us an opportunity to reach an even greater portion of the multi-billion-dollar sequencing market.&#8221;  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;It&#8217;s exciting to see how seamlessly our SBB chemistry ports over to the Apton system in our initial trial runs,&#8221; said Mark Van Oene, Chief Operating Officer at PacBio. &#8220;Acquiring Apton accelerates our development timeline and is not currently expected to increase our planned research and development expenses.  We can quickly start integrating our chemistries onto Apton&#8217;s high throughput sequencing instrument, which we believe will significantly decrease the time required to develop the new platform. Apton has delivered with a lean and agile organization, and we look forward to fast-tracking the development of this new sequencer. Additionally, this comes at an opportune time with Onso entering the commercialization phase, and the Onso development team looks forward to leveraging its expertise in this new project.&#8221;  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;At Apton, we&#8217;ve been relentlessly pursuing advances in both cost and throughput to address customer needs in the high throughput market,&#8221; said John Hanna, CEO of Apton. &#8220;When PacBio announced its Onso benchtop sequencer, it expanded our imagination of what a high throughput sequencer can offer. We knew that if we could complement our advances in optics with best-in-class chemistry like SBB, we could have the potential to develop a truly differentiated high throughput short-read sequencer, the likes of which hasn&#8217;t been seen before.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Transaction Terms </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PacBio&#8217;s acquisition agreement for Apton provides for upfront consideration of approximately $85 million in an all-stock transaction consisting of approximately 6.3 million shares of PacBio common stock plus an additional $25 million in stock, cash, or a combination of stock and cash payable in connection with the achievement of $50 million in revenue associated with a high throughput sequencer using Apton's technology, for an overall transaction valued up to approximately $110 million.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PacBio has also posted a presentation in connection with this acquisition which can be found at investor.pacificbiosciences.com.</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Advisors</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Allen &#38; Company LLC served as financial advisor to PacBio in connection with the acquisition. Wilson Sonsini Goodrich and Rosati, P.C. served as counsel for PacBio, and Fenwick &#38; West LLP served as counsel for Apton.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Webcast and more information</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company will discuss the acquisition of Apton and its financial results for the fiscal second quarter on its quarterly conference call later today. The call will be webcast and may be accessed at the Company&#8217;s website at&#58; https&#58;&#47;&#47;investor.pacificbiosciences.com&#47;.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August 2, 2023 </font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time&#58; 5&#58;00 pm ET </font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Listen live via the Internet or replay&#58; https&#58;&#47;&#47;investor.pacificbiosciences.com&#47; </font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Toll-free&#58; 1-888-349-0136 </font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International&#58; 1-412-317-0459 </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If using the dial-in option, please dial into the call ten minutes prior to start time using the appropriate number above and ask to join the &#34;PacBio Q2 Earnings Call.&#34;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:112%">About PacBio</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PacBio (NASDAQ&#58; PACB) is a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our existing HiFi long read sequencing and our emerging SBB</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> short read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow &#64;PacBio. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:112%">About Apton</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Apton is a Pleasanton, California-based developer of Super-Res&#8482; sequencing and single-molecule detection systems for large-scale clinical applications such as early cancer detection and population sequencing. Apton has re-imagined the optical systems for sequencing using super-resolution to evaluate molecules spaced closer than a wavelength of light. Apton&#8217;s Super-Res&#8482; technology sequences tens of billions of reads in a single run using simple, un-patterned flow cells that lower variable costs.</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This press release contains &#34;forward-looking statements&#34; within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the&#8239;U.S. Private Securities Litigation Reform Act of 1995.  All statements, other than statements of historical fact, are forward-looking statements, including statements relating to PacBio&#8217;s acquisition of Apton, including the potential benefits of adding short-read, high-throughput sequencing technologies to PacBio&#8217;s product portfolio and the synergies such technologies may provide with PacBio&#8217;s existing offerings&#59; forthcoming PacBio products or technologies, including the Revio, Onso and Apton systems, and their future availability, use cases, performance, and specifications&#59; goals and operating plans&#59; and expectations with respect to development and commercialization timeframes.  Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety.  These statements involve risks and uncertainties that could cause actual results to differ materially, including, but not limited to, risks related to our acquisition of Apton and our ability to successfully execute on such acquisition, such as the failure to successfully integrate Apton or to otherwise realize the anticipated benefits of the Apton acquisition, as well as the other risks, uncertainties and other factors discussed in PacBio&#8217;s most recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on May 4, 2023, and in PacBio&#8217;s future filings with the SEC.  You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances, and other factors that are, in some cases, beyond PacBio's control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Readers are strongly encouraged to read the full cautionary statements contained in PacBio's filings with the&#8239;Securities and Exchange Commission, including the risk factors set forth in above-referenced Quarterly Report on Form 10-Q.  PacBio undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available, except as required by law. </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contacts</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investors</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Todd Friedman</font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ir&#64;pacificbiosciences.com</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Media</font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lizelda Lopez</font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pr&#64;pacificbiosciences.com</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>exhibit993-pressreleasex08.htm
<DESCRIPTION>EX-99.3
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i887027d25f134195873de72bf4082036_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PacBio Begins Commercialization of the Onso Short-Read Sequencing System</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Onso platform delivers extraordinary accuracy which creates new possibilities for research and translational sequencing applications</font></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:112%">MENLO PARK, Calif.,</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:112%">August 2, 2023 &#47;PRNewswire&#47;</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#8211; PacBio (NASDAQ&#58; PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced that customer shipments of Onso short-read sequencing instruments will commence today. As previously announced, the Onso system is designed to provide extraordinary accuracy through its novel sequencing by binding (SBB) chemistry in a user-friendly and flexible benchtop platform.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;When we announced the Onso platform last year, I knew it would be a game changer for genomics,&#8221; said Christian Henry, President and Chief Executive Officer of PacBio. &#8220;We believe PacBio is the only company to offer both highly accurate, short and native long-read sequencing technologies. We believe this uniquely positions us to offer more complete solutions to our customers&#8217; challenges and help researchers unlock novel insights in oncology and disease research, among other areas. I want to thank the Broad Institute of MIT and Harvard, Corteva Agriscience, and Weill Cornell Medicine for their invaluable feedback, helping us to improve this cutting-edge system and bring it to market.&#8221;  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;Over the last several months, we have tested out the Onso system to understand how high-quality sequence data can be used in the context of germline and somatic applications. We already have some novel findings and are excited to see where the platform goes from here,&#8221; said Niall Lennon, Senior Director of Translational Genomics at Broad Institute of MIT and Harvard.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With Onso&#8217;s potential to achieve Q40+ levels of accuracy (one error in 10,000 bases), we believe scientists will have the opportunity to gain more insight into ctDNA research applications like minimal residual disease (MRD) monitoring and other &#8220;needle-in-haystack&#8221; applications which require highly sensitive variant detection. This may ultimately allow researchers to detect rare variants missed by other short-read technologies.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;Since we started testing the Onso system across a range of different applications, my laboratory at Weill Cornell Medicine is seeing impressive data quality well above the industry norm of Q30,&#8221; said Dr. Chris Mason. &#8220;We've had several runs with raw quality scores in excess of Q50, which I have not seen using alternative technologies. We see Onso&#8217;s capabilities opening up new possibilities for research and translational applications where accuracy is a critical need for success.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we believe this level of accuracy can add value to common mid-throughput sequencer applications such as exome sequencing, single-cell RNA sequencing, and targeted panels to support inherited disease and oncology research.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PacBio plans to launch library preparation solutions to support a wide range of sample types, and library conversion kits to allow existing third-party libraries to be sequenced on the Onso system.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Onso system is designed to deliver 400 to 500 million reads during a 48-hour sequencing cycle (for 2x150 paired-end reads). PacBio plans to offer 200 and 300-cycle kit configurations enabling paired- and single-end reads. The system list price in the U.S. is $259,000.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Onso systems will begin shipping to customers across the globe, reflecting the global service and support capabilities of PacBio&#8217;s commercial organization. The Translational Genomics Research Institute (TGen), part of City of Hope, is one of the first customers to receive an Onso system.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;We are excited to bring the Onso instrument in-house to TGen. Our early access data demonstrates the ability to accurately detect ultra-low variants without the need for high-complexity error correction across a broad spectrum of applications, including infectious disease and liquid biopsy research. We believe SBB technology will positively impact our research&#47;clinical mission to enable early detection, monitor treatment response, and track resistant mutations,&#8221; said Stephanie Pond, Vice President of Emerging Opportunities at TGen.  </font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;With our first shipment of Onso today, we have launched our second major platform this year. I am extremely proud of the entire PacBio team for this remarkable achievement,&#8221; said Mark Van Oene, Chief Operating Officer at PacBio. &#8220;Revio, our new flagship long-read sequencer and now Onso, demonstrate our commitment to providing genomics researchers with powerful tools that have the potential to revolutionize the genomics industry.&#8221; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PacBio expects to complete the installation of the first Onso instrument and ship related consumables later this month. The milestone payment associated with PacBio&#8217;s acquisition of Omniome will be triggered once both the Onso instrument and related consumables have been shipped.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:112%">About PacBio</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PacBio (NASDAQ&#58; PACB) is a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our existing HiFi long read sequencing and our emerging SBB</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> short read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow &#64;PacBio. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.</font></div><div><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This press release may contain &#8220;forward-looking statements&#8221; within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995.  All statements other than statements of historical fact are forward-looking statements, including statements relating to the availability, pricing, uses, accuracy, coverage, throughput, specifications, advantages, quality or performance of, or benefits or expected benefits of using, PacBio products or technologies, including the Onso system&#59; anticipated availability to ship sample preparation solutions and consumables for use with Onso&#59; anticipated milestone achievement&#59; PacBio&#8217;s unique positioning as the only company with long- and short-read sequencing technologies&#59; scientists&#8217; use of Onso to gain more insight into ctDNA research applications and detect rare variants missed by other short-read technologies&#59; adding value to common mid-throughput sequencer applications&#59; potential to revolutionize the genomics industry&#59; and other forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to the following cautionary statements. All forward-looking statements speak only as of the date of this press release and are based on current expectations and involve a number of assumptions, risks and uncertainties that could cause the actual results to differ materially from such forward-looking statements, including, among others, challenges inherent in developing, manufacturing, launching, marketing and selling new products&#59; Onso remains subject to additional development and validation&#59; potential product performance and quality issues and potential delays in development timelines&#59; rapidly changing technologies and extensive competition in genomic sequencing that could make the products PacBio is developing obsolete or non-competitive&#59; supply chain risks&#59; customers and prospective customers curtailing or suspending activities utilizing our products&#59; the impact of U.S. export restrictions on the shipment of PacBio products to certain countries&#59; and third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio&#8217;s patents or proprietary rights. Readers are strongly encouraged to read the full cautionary statements contained in PacBio&#8217;s filings with the Securities and Exchange Commission, including the risks set forth in PacBio&#8217;s Forms 8-K, 10-K, and 10-Q. PacBio disclaims any obligation to update or revise any forward-looking statements. </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contacts</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investors&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Todd Friedman</font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ir&#64;pacb.com</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Media&#58;</font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lizelda Lopez</font></div><div><font style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pr&#64;pacb.com</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>pacb-20230802.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:21c8f849-4733-4e48-9f95-0792ce893515,g:042e2ed6-378d-4041-85fa-b761f8270455-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pacb="http://www.pacificbiosciences.com/20230802" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.pacificbiosciences.com/20230802">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pacb-20230802_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pacb-20230802_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.pacificbiosciences.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>pacb-20230802_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:21c8f849-4733-4e48-9f95-0792ce893515,g:042e2ed6-378d-4041-85fa-b761f8270455-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_f65a2ccf-3aca-4e7c-9b9a-ab3348a6f549_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6d8f499e-6539-4fe2-ac30-5ef38a338dbc_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_f91e10af-a027-4e5b-849a-430ab7f6da60_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_dc324ec6-d281-45a2-94c4-b32054de7bba_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_1d030b75-67bd-48d0-a517-2b153cee631f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_fd50198e-8d68-4c2b-9680-6ecfa85c6e71_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_c534363e-3f7a-48aa-b10a-f8e2e4725787_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_280fbab7-2227-4986-9afd-bf211aa53171_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_632e8be8-72cc-421b-aa70-62b53525c3ed_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_96b2174b-2235-4128-b562-7cfbbfb5e203_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_db310501-5eb1-4993-b54f-ef10dbb7f85b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_28719332-3ce5-4d20-9405-cdb9080f5387_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_9a020f1c-bc96-4c6a-95ce-86c1eda65fbf_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f715d643-bcb7-48b0-9499-599db08d9377_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_d526e950-5175-450a-b30c-b6939dcc703d_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_30f1bac5-ee64-488f-8373-686ab13b7363_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_fd0d93ce-baa8-482f-a558-95a46a816a54_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_71561236-e5a8-4a69-a79b-b0aa87bc04ba_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_db42a815-f933-4dca-8f77-06982655d461_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_4d24e1cd-be1d-4bca-801b-92d9e1aac568_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_80334724-66ee-4711-a755-f78038fa468f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_f6df1af9-e228-4e6f-9500-856c3d1c5af2_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>pacb-20230802_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:21c8f849-4733-4e48-9f95-0792ce893515,g:042e2ed6-378d-4041-85fa-b761f8270455-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CoverPage" xlink:type="simple" xlink:href="pacb-20230802.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_1f81b57e-15ef-40fc-bd15-aa65799e3ee9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c41efd94-4b0e-4298-a5af-89cd8040f306" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1f81b57e-15ef-40fc-bd15-aa65799e3ee9" xlink:to="loc_dei_DocumentType_c41efd94-4b0e-4298-a5af-89cd8040f306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_31d2cd8d-e0bc-496a-93a1-d28aa77df92e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1f81b57e-15ef-40fc-bd15-aa65799e3ee9" xlink:to="loc_dei_DocumentPeriodEndDate_31d2cd8d-e0bc-496a-93a1-d28aa77df92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_0f8897dc-a036-40d0-8696-b172416f6987" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1f81b57e-15ef-40fc-bd15-aa65799e3ee9" xlink:to="loc_dei_EntityRegistrantName_0f8897dc-a036-40d0-8696-b172416f6987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_e1e92c9c-0707-4c9e-9ce1-71bf186cad0d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1f81b57e-15ef-40fc-bd15-aa65799e3ee9" xlink:to="loc_dei_EntityIncorporationStateCountryCode_e1e92c9c-0707-4c9e-9ce1-71bf186cad0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_0e583c35-47d5-4a0b-bd8c-7cac2446c570" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1f81b57e-15ef-40fc-bd15-aa65799e3ee9" xlink:to="loc_dei_EntityFileNumber_0e583c35-47d5-4a0b-bd8c-7cac2446c570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1728ec78-2477-4fa3-a2cb-44d0a659ca4f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1f81b57e-15ef-40fc-bd15-aa65799e3ee9" xlink:to="loc_dei_EntityTaxIdentificationNumber_1728ec78-2477-4fa3-a2cb-44d0a659ca4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e2225679-ff7c-463c-8ef1-84bed032a6a6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1f81b57e-15ef-40fc-bd15-aa65799e3ee9" xlink:to="loc_dei_EntityAddressAddressLine1_e2225679-ff7c-463c-8ef1-84bed032a6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_09703048-7ec0-4098-8b1a-35b3982d2b2d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1f81b57e-15ef-40fc-bd15-aa65799e3ee9" xlink:to="loc_dei_EntityAddressCityOrTown_09703048-7ec0-4098-8b1a-35b3982d2b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_8900adf9-7f0f-49ee-a3a7-beaa9100a34a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1f81b57e-15ef-40fc-bd15-aa65799e3ee9" xlink:to="loc_dei_EntityAddressStateOrProvince_8900adf9-7f0f-49ee-a3a7-beaa9100a34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_379eed0f-41dd-4720-8e98-b98533da536a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1f81b57e-15ef-40fc-bd15-aa65799e3ee9" xlink:to="loc_dei_EntityAddressPostalZipCode_379eed0f-41dd-4720-8e98-b98533da536a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_11935709-8ea5-4a55-9bda-1ea2935bb903" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1f81b57e-15ef-40fc-bd15-aa65799e3ee9" xlink:to="loc_dei_CityAreaCode_11935709-8ea5-4a55-9bda-1ea2935bb903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_5e918c93-d869-4279-b65b-6922b0358a6f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1f81b57e-15ef-40fc-bd15-aa65799e3ee9" xlink:to="loc_dei_LocalPhoneNumber_5e918c93-d869-4279-b65b-6922b0358a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_f6ff8e9e-8a0b-4f5f-a094-2c053eac2847" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1f81b57e-15ef-40fc-bd15-aa65799e3ee9" xlink:to="loc_dei_WrittenCommunications_f6ff8e9e-8a0b-4f5f-a094-2c053eac2847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_b63452ea-db43-4538-9879-b47b1bab92d8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1f81b57e-15ef-40fc-bd15-aa65799e3ee9" xlink:to="loc_dei_SolicitingMaterial_b63452ea-db43-4538-9879-b47b1bab92d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_adfe4c01-a2b6-4f4f-b697-2bb426bab684" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1f81b57e-15ef-40fc-bd15-aa65799e3ee9" xlink:to="loc_dei_PreCommencementTenderOffer_adfe4c01-a2b6-4f4f-b697-2bb426bab684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_a0fe989d-f44d-427c-8f10-f2773718f342" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1f81b57e-15ef-40fc-bd15-aa65799e3ee9" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_a0fe989d-f44d-427c-8f10-f2773718f342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f52bfc14-2b73-46f0-9c7d-48e3e12269d5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1f81b57e-15ef-40fc-bd15-aa65799e3ee9" xlink:to="loc_dei_Security12bTitle_f52bfc14-2b73-46f0-9c7d-48e3e12269d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b77eeecd-8967-4ac4-a93c-d40cb893000b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1f81b57e-15ef-40fc-bd15-aa65799e3ee9" xlink:to="loc_dei_TradingSymbol_b77eeecd-8967-4ac4-a93c-d40cb893000b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_4dfe1f1c-4771-417b-9fdc-d3bd5fef7d5d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1f81b57e-15ef-40fc-bd15-aa65799e3ee9" xlink:to="loc_dei_SecurityExchangeName_4dfe1f1c-4771-417b-9fdc-d3bd5fef7d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_4a2e0edf-93de-4cbc-bae1-fb92be88ef78" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1f81b57e-15ef-40fc-bd15-aa65799e3ee9" xlink:to="loc_dei_EntityEmergingGrowthCompany_4a2e0edf-93de-4cbc-bae1-fb92be88ef78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_9e42b52b-80a2-4c68-8348-b3404874afca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1f81b57e-15ef-40fc-bd15-aa65799e3ee9" xlink:to="loc_dei_EntityCentralIndexKey_9e42b52b-80a2-4c68-8348-b3404874afca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_df66b22c-d76c-4204-ae2d-6286c916645d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1f81b57e-15ef-40fc-bd15-aa65799e3ee9" xlink:to="loc_dei_AmendmentFlag_df66b22c-d76c-4204-ae2d-6286c916645d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140107126518144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Aug. 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  02,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Pacific Biosciences of California, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">16-1590339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1305 O&#8217;Brien Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Menlo Park<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">521-8000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PACB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001299130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>pacb-20230802_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="pacb-20230802.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2023-08-02</startDate>
            <endDate>2023-08-02</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0001299130</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2023-08-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Pacific Biosciences of California, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-34899</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">16-1590339</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">1305 O&#x2019;Brien Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Menlo Park</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">94025</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">521-8000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">PACB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( %B! E<D'INBK0   /@!   :
M          "  <@1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( %B! E=ED'F2&0$  ,\#   3              "  :T2  !;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /<3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="pacb-20230802.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="pacb-20230802.htm">pacb-20230802.htm</File>
    <File>exhibit991-earningsrelease.htm</File>
    <File>exhibit992-pressreleasex08.htm</File>
    <File>exhibit993-pressreleasex08.htm</File>
    <File>pacb-20230802.xsd</File>
    <File>pacb-20230802_lab.xml</File>
    <File>pacb-20230802_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "pacb-20230802.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "pacb-20230802.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pacb-20230802_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pacb-20230802_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "pacb-20230802.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "pacb",
   "nsuri": "http://www.pacificbiosciences.com/20230802",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230802.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.pacificbiosciences.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pacb-20230802.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001299130-23-000093-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001299130-23-000093-xbrl.zip
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M-S]$?H^\$;]_BQEO #:(5A'<1G.(=D$8XIF,?B<PB8MLDL3Y>#++L[K0%7+
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MU\&"@QQB&.6Z[ZRRG:8YYG!LVZBR-#,4 3Y#AD[!E1*.K=&S^L[7(&G1'8(
M(BIRRR! 2\AO,69'@IP14[=TM!3LBS^AT5C*68.1'?W)@4V/O!%_BE^^E?:H
MB!? ;D5L'&<RIJQ>'H"]*Z)L,HG#PLE[@+_%F"US>GM-3&UJ7+/LJR+> :,.
M%CF72;<Q!?),8Q3X?+JA>@6*1#JGX,,()0&JA(GJ4U)]"0A;E&@U\2Z24AZ
M_DD@A.+@YOP/BY(Y:C26\J"4U)L)9^ M?6%^+G3K[R-0!1C@B"$P)9 Q.JTF
MG$H7";\M] KZ$:B+8%+YB/H@]2+\$VHL1*TH8C(8)6+WI3H0&8T\!5<!E*;4
M5??LVP37S(1>*S\#CVLZJ[LU\$)!A1[Y\.V4T%!D>YAPZ='A$EED$47 >'<B
M,*TEBLJ83R0@1!^@)D+"PI<*^&C$$N&G9>*)*NI;)([*\*_4T5@\!$U8M-GA
MX#C@AL0(,!;@:]3F#MCG65'J***@<OJ$-8[1-?@N'0HNY ]#7J3\VI"W'IK7
MDC$^G6'V!;]7SU9)=2"=8*"(C'M&87P/SG08]@14#IQC7]^"^Z]*,D!A"?8"
MB6]H&((_@?9-)M$Z61[XE4;@] JNB)3:),8@IB;K_F)%/JX(. \!"0A/2CBX
M# \4R**-]6%=H&Q\+5IC,^*(AEE=)[/>M$?>TQ2>C\@??,H NZ(P$2=8))^3
M$#0+BTHO1LQBB)(D=8)QX7G>A64/+G3#<L%S0?'(4/=(KZEW"_[5TO=MP[RP
MC/Z%;CL#G!@@4,;S\(8_XT(S"HNLEYKT7R;,L$CM(V,%%F4N4\RG3$?>LZ&/
M=0!42K*GXH[R4(!=UO$A;ILO_"P('.$)$&*&OYMDV2P55!&]?.(/7E"B-Z,^
MND_#(G$!?F$/%$_S#-%^)>(:XM1RD9W$_4=)SBH1Y,O@6S2<Q\!H6B8B5YN[
M>2J\#(CR ?#P=4:*$6KI]2I;*10M/ '^.!\C?K1: E-:I0=&K<PZU@L&&-T*
MU2B&$XJ8E3YUFDDON8K#2S<?31NZV-.9L.( :EX/_VL%#9EG$J. C/*I<)^$
MR,;A796C )S/BQK!%S2R,(<I^-R_@RTJ/7 98BVH(-ZV9!I$Y6.4Q%.2W<<;
MC*(?+\40(K\&"D?D^*L2B(8Z!Y,;DHAE[2*"*$HKNF^*A@AA+=D7+F5<Y#!$
M6;.>:UW*Z<I\B7@*_(/QHB0JGKA=JJ_\4*NO[-)[=WM.(_=])6N"TG1AB:>%
MZPQL*S:G8%(2!WCU[H]?]QYHO'JW7'U:1DT0 -;2&LZI+UJD*!EB\(>I)>%4
MS&8A+$A\I1ZBUK*E(K^&R3'I=]((T!R6 BH>&HGH$WR8(J\F99##"T&WXN0P
MN><7/RW:$BLHU"?1(S^!5I\B7OG"TFN%NTCNT#\C]_?WJ+V'J*]EV!J'Z-1\
M\]HM/?7.M0Z(4**LFE1LDK$V)A>"PIP5"85<A/_A'#LO9#<?_@8LZ2(ICD^"
M6L,&M4.O=KW)NLU ^13-W&.:!-+3%4YJ%$?H#NC>E6@J6>SF*5ON#FV$UTL<
M>B<WA1T"ST.D>!XLI;X="?0#L$D$51RSJ8'HG@$I*VW#<B.-5OM8JQIMM*7F
MQNJ?11.E$*?5OC>,VX. %TDAK6AKS&34D^;#6H8.A!-FRD2Z'!Q0^#'D8%X*
MRYCF0NTO?&ZPO&DNFH$3,?(:UH&"]'-9&.;"O$"L*[)F(DN 5 (GJT[*Y5=6
M[9>+H9=4P?T$75?ZF6$'<QB6'76:\&R'F( /9Z,\E,FPTNNM+;#*YF'56CC"
M_KRR>#2A0YGA%Y.=H>NYF >L6TP$%M,C_Q/?8Y%)>V+"2+%%SRK" NA7E*Z6
MOXDOR!,P0.@Y1;BB"? KY%.>%5VJR#YL+:3A7&80LS@NTH&3. \ECX=,KBPH
MXE"80%QV'23K$+!AWHM);^3BAP7,M$*K2S<-70QD1P4%DL(R0HKQC]B)NJ;+
M=N&TP)?0"-"Y5!=BW.I;F,>XHV%>A,D\J7,%D!Z*O@[IK_B"*$"&W)>Q"XP'
MT$"7IO34"@Q6F:HUS*Q>35-!\")M*M "M(W6A0R=R%XYRRH+8J,UBY(>I5AR
MZ=X)>-"B\C41=3@IFFBO1.P8E.DN"+2FQ8ZMY8;J(<ONL0FDWE7]A,JOVFW%
MV(785(U?,C:DX!ID_.^JB:;(J(A\"XW&(J])4_!NTJ+]#F4.G>--+Y4M+&DM
M.[-NK"*[DY2I.YE  OYG)8Y <H%4J>PXS^5>@B"OTFAB#X6,Y<O./%(TY1D]
M<BNU[,.W8O(NX4,44YA>N8T#@X=$$D T4* ?4:>*B)QAFN /\JJ (+=O(+<S
MCE5Q-A?,!&' <J1\'%MU:MD+5#X5#7$-;#02C4URQ:EDOK U#WA;EU58"@"F
MIHEYH<#^+A..N-A4=%\);5LK0RP,VY+B7=(ZT\6$1;UW5:T4?5@RQ[@J\+6A
M2>GSXS/P2X:9!QF"I1GFY<:\K!.+L"R6*4:PS)\%&^I#L2^8?1$1'L5$,:Q,
M-(R#]@,JK"FL/*8QSKR\>RB%"0(+LIS0L5!.)8 13P F*3JEI17\+WV_A4H5
ME<1[!@))B^Q>W?8_$)NZ\2TKJ\MJM=*J4OX*"UV&;S Q$3C)F=7:$O#%0VQP
M!#GKD>N'@VYA"67FD&.D!L"6!<@BEX$>%";G'CX$['O,)13J1K0-5@%186(6
M(Z550%'LY'G*8G0R+(( ]QZBH8M?XO@SZK8J3&JZW7_?,<]#N@J[A"JM3.F.
MBA6%Q8HJ/J7B"\:58'/!3H!#5&3*;HNRM6F\+T%XBW9+%JK?EQ7&:U\6, >6
M+>2)3H4AU2HAP8PT-A2(KL;:"+_ 7V.)\4],E,6KH08."$)8@U1:^)E@Z:.E
MWXX($  $7U;LJ2^]H,U+KJ=1:N-(+2U3XCCG(HW-9<(-39=6R\3Y,;:OC9DF
MLY<9JJ J/X?.<=W4Q*,BAHO8"$4]3HH>9!;4?CF2+<X:>9B$P$"NEAK\YK4S
MN-K8+5Q4KA9+7.Z3JK].UL%KB3YMM;ET3:ZPZ/^L=V*+XB-&VZ,XY/%BU]8\
MP@P2[AE _VEI! P>"D7RH/VYREO&&&U@_4&N6)*L\%[%(\5^K7K9LRSC8@ 0
M;TS3EFT6$*G?9^C8B>^6&EB^KEP$!XTI05FKM*8/*2RJIYHL@>*3LLFWZ/#M
MP<=('>&%2PLDT@))4+;+54.(#\0HY9D&&P-'T80?%'DYG-_"DURX8O\_SNLC
M@&\$> 3+DPM?BDMX1H](2Q685RXI!!]_%E0'SS"?S@KK!J'6YZ+JC 77!#50
MU= B STY$B;^ 8IQGOFBUU,VJI>ULB+*))B2Q[TA8+5$?%!TP:"[!L-B\T2-
MGC5V:!@1A2&+I%,P$0&K2,S5BA!+!0B-A!1F/"D^23ZSK'1]4_ ,\.=EU@NG
M&+X/#!/?6TP'OY?2D*W@H\92":]:ZR(RH;;MH,)_K7PLH5( <X7H:VA>-OZ7
MRJS(F2#/,O"4@7TXU45#@.0!/EX)AER()'XUI^H).1?Y^MK+UI3II2B4]87:
M3$ I^"!NTANJMSZ@LJ@-HA6_2:6W 6I9=%P]&&#1X"Y?*-)?TF;<8Z\6*+@0
MK*HD1XUE=8V(GQ737;Q>KG19%0B#!@H)A+K:)B8+^4632:TMXJ$Z1VTE.45$
M()I4.CVA,QZ@EX9F=47GRM8S0$W*90N&B%6*?=E%):"FL.60>51?:WF,C@CR
M_#A=V"),2LHGD(Y)DL^*]:!&#2%DJ-IGT#\6[7@X@SB2-G@AKFF5LEPN\J$-
M7,FNPXJJ?ZP4SA[*265G:I:5RD*\0!3'#JYBT.JAQ>3K);F,3T5=*%WP%D*O
M5(3VY:[8SZ#NV'06QG.&XESKJRDSA+P2@V4Y@HF6^XAKGX#^ IX+;2(&@*_(
M.AK%;TI_2.YQJMNM<H(<E#-F,P <(>5X6@ZHN+'4$B,D,"OAAIR.%L2M-DF)
M<^@$JU+&/A>.#@1-0#S<UU>SY\4 <;+F^85M+(ZND/KGP5:F*1:SR@9KM%DR
M&9!6@EPI*VR,X1AJ2;V+E2P8'-O)+TJM$L;^YR"^1VTG_5X06(3R*"SSS50D
M4F1CNIR@U&=KYR;P'97YW"*#(70IG<9(?5P71F%%!J-P*D5@B4DF:<EJUHF*
MK$MIU4I#!EH=[?4()%Q$/Q5Y14 &X1BR:R3P4'@S#[QK7$'E8>/./, W7W;M
MUHY9ECU +T @ TCQ+OZ?1@P=_\0QX:=_E7MA938QF\1IE3:48BB[3H0.*&.(
M3T!-\I.D1*\,&_X08>XCW@,Z#')K")YG4C2R+GERPLS.&/TL4NH(CD(1"U2B
M^8Y'I0/HLYDHD6 #BT@$#N=@N^\KS8)M.H5X1*"CAF$97<CLG&C934@N-K(6
M(?HC<Q</C;!^03"S)T7"YXF?3S%L]UFE%*7GI8FO83<.VM9ZL@!\*.GIE*TQ
M!X]\-Y?/P&( NHI-@P$:!KE],)9Z(E@7[A>B451Y"W]S*&QN($U-]">(?)']
M++ >B;96K'-C*_9D24@6[672<R[1+- K"TP@.Z5(-Y.<YKW2M>,M_P3]S4?S
M_28@;C!\]YN?+GCH^5:]:Z)GJ)O(CH. _ 2V+ #'X6 %'S$5U]%[CFGT/-O1
M#SL3GHB&C+)3HY/).-R21M?C:J^T^@6^&P:4_ (>P]^'G<JL(=NZ48QH?H9Q
M_]7!"AB=/>>X2<?F1@ <>/K_KCR)F\J3N*E[$HO^(^SFKSSQ ZY'#'2) 0GW
M&TCB&^'_R0W,\CP9=% 7!^_(S3WIV^::-9-]KJ4H8MKG IMHZ"QEE^4/5^#G
M8E?U)8_$G,1#5\58A?RNZ884Y),?+T2DITLQR4 VLJ!\<_%Q3WST71:L?N8,
M>@-W\\=ZS]CXV6/#&D;/[CM;#?OX9[;NJLGVO4;#?B? ( $!F$LA)/_'*^O5
M0B>+PL&E3@Q NT[Z KGEJ-4#AK/RA#G[@L^LZM65QEV!TAV)=[^1MOICDC!&
M?H7O35+R'NM7E=3NCB:+!PK91LG')X12)+BVJV,@UM*I[4MTVG:U@G"G3+)?
M1=MPT5*D:-8:9N8VXE@LCN#?_>5%XO;?O2YQO0M1G'R_'.&\,"A>&C\B5=P!
MVLH->0VHNE."+ WR!$[Q<(%Q@CGBBX(4OL_8:/20N@+ IM-)!'\LZC)E^^-#
M>K=9JD[6P*DCZ_SJ60OKHGS8EN8ZSGHIV0:@+1;YF(0]]<J'4JH UE6 638
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MJEY?/$*'H-CS;/41R>YWWP]13]<GL?3G, [F\-<DFX;O_A=02P,$%     @
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MX@+D%Z-$G+73UL/0),'6_/&KPZ>G[Z_>JH5?0!?X5Q@>$02>@.$&;"-Y1!&
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M9@PVF:PKK&P[>=JB (^ER#5]P)>:7>.69#IQC(00#U/)CJ!D=.G]O=/70I9
M1>V APX&6Q9R2D_!C75(,EJ2V^Y/:R"QIK"N#, AA2&8U+9AYIFAQ</_2P$X
MI)GU:WO@Q<:13N6V]<)GTJB1.%_V(&"TM6[;.I^?;UGQ]8O)?"Y9H^_0#Y')
M6@+)NM'*]TA4GVJ5-8Q%0+94+L-MP/N[];3G1B%)&8@IE5@H\(6?50!^PE(9
MGPHO=2XN9@Y0U5CUO:I(_]Y##CHG.!*M%Y?O2)\"30!;E.B'&324;8_7I#^D
ML!GT$%O1F\P(8AB@#3Y--_Q4V9I&X_YYF^TR,BQ5?%E8Z+:0QE93HH@WI%^V
M%\=+@WE3/:=O6N(T>$[;M!4,,1& U[(9?0]"*C'EJ-/Q270#W)* P[2ET:ZD
MN35&NN%9\'XWJAEU//P?4+ZF!Z/ZE&G&,ICA%4 !R^B5+ UP"%@3?PG1*_-%
MO($])=W!*\2>X&>"DR%EI7<T&,R:YNBG:^'0UB#V U@F_@Z^OT-,"&\[TZH0
M[VH5%>M=46AR+%#"#F:1]!"$TIIPK.P#3\\'YX/(L]&E(AX$#?,P'$@L6D<F
M%%<+RA2<B:XHX? !3U$G@ TPPC$\\K5]Z<W**P_L?U30U$J INP&>\(%NF;+
M1'3,TT3CYZW_ %DK1Y"(Q4R#%NCM!)<"-2&Z)(>HP2S)=\I5O ?)A:Z/2W P
MD ^UC1Y6:M'KR"CRD@QEM(N=2>9XIF(.R*F&OUWWD/0]*#+6W@CLM)".#R)#
MDT+-LQM&%H[+UQ."AFP%D3!P6F=YSG9#&L,NG\U'"9;)9JBX\5Y,W;O*VQ +
M=><,S2+3*&K<2@5*:0&_L@82@)TOX(<W,%CA<&.20>-9XC )8"SPW1,/<_43
M(/0_I/AG31 UT*0B_N8$*-@^!S4"AH+:UZWS+7O!X*O8"8.*F6 W&9C9 Y9B
MSCQG7YTAWH+0'/BC<A^XI;80'@SFND7XBYW!WT#S9-)Y&":UU_R/,U 9'>$J
M*B;IL$PG@-$,"<@*4@E%RY <J"5G2U:I))'*SK8O*#K8X3K[N)94FZ.O$2GZ
M#<D\A*(%H3ZSK0E1LPFQ-QTQ9%CT[PS5B8)*($7*C"0V]>;4Z!N.&9+5CC,Y
M5[L"ELY5PB*0JG\F&MP1IR>\*YWHP_7)H$ ].E/4!"1X^C%1T ;50?LA 'LK
MT^:<[8/#RS)CD7Y0\/</5 GW^ZK *@X<Q$JK! YLC^88YF6.&(?MDFCKPA&E
M'%'EL8S"M94:ZSX!V8T"*KX^/A)E"%0(@62ZC4FAD]D-<+-B50S,8LJTOL>3
MT4&_AY])%] 2-8\,+'W/.]8F!%6R-]WBZ_TU GA= D7RLP2^H\^U>O+#1ISO
M80VRPB6G=9I)K%2@EC6(L(M@C5Q?YT:^/MH;'N8HB&NQRGN;!;6(3NQV%0^I
M*S/\L1\$[@ESG?2?'($Q:]R;2]-2<;)FT[<N@/&XIVGTD#U"E"?Y?&E@/VL8
M=MQ)"DK)P-\@H9URV(CS@QTA6SE!:@V[G)/+UM4<)L^Z42TS"E FVOI,$]/]
M"!@8_5N<Z7@R++N"8#[_!)X+Q,[55B&V>PO,@E,ZV5N](B=<:-E^Y3.UV_!S
MYKJ=:V1MZ016]B:5!<*0$VD6<ND?_<;UXB]J4<_RN?;6^8<+W3.#4 5AP<'Q
MJ;B(1:LW;RZ@U6Y.$(;%A(6I* HD?TRW(46-B+_5M/2(AK?74(E*7).5K+3X
ML[6YTS$3N+(><$-2/+H8#8Z$[T9.8-AL]-5 +'^EJ@62@TCN1^@$:'U_RXLA
MXGD(G-^-C8]J C,= L 2\0&820D$VXJ'0/5NO'R >#N<<-*4:X] U6_*O8\Y
M0\+8#'$$H]B:)OAB>JW05!*"&(&E'/D?\CXJ]5;\6OP5[@!/.4K+*$_$R8;K
M"US:'0FBB[]EHF \%T/VRB5]1?DM5\BH'K6Z1Q]$X!40CW5(Z8\ L%G3U)X_
M<FV:?WS&%/.:A^JKN)WR$EP+U]LHQ]\O61^0B :RCOB?O3U1E^+RPSV3]88K
M;H+R>#'7DF'SFI+D2C44@SF%Q'_YW\'EOCEO$=46")G#+<;I\?%Q>G#X+-T;
M'SRY9]H"JV6(ASOZ#L?[Z<'X:;IW>/3L82H:6\K710R(N68#NY?&-)9*!DAS
MJ;1$7X<F1M/9+X(;HIR6BG"UT\'=AEH8%VM6>W*PC"54*:_:<D(UO@E"[%!A
M\C?TXD\VE@W@,@]/H]?^<5]<2E=A'T^].3/BAP^!D[=$41/;=L7+AT#EG4G
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M;)7%3PP*6,L!+(;DC,0KF./-6+TWYG,*?<5BL2!G/R'WSAL6\*]V 0/\I#/
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M@5:=+[]M87!&?DD_NPSX[NM]4<U);M&=T[V#J[=#;D7Q8K),_(@XRD#/WZT
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M,4D=E-A%1;[PZ%V&:!DXS8#<U ;\B;G&@'JX9<FL=N9,?;$T86&>PI -6,A
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M>^[)/>0/1$HJVE73><>RWJ3UQD'3?N?<\=(=GI\LIC4<MGT]^PU02P,$%
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MW$[0+2V-5-@:K=>$ZZWPV@J\C>"N0G\!VH81O#UC#L(_P$:/!-#F>>!$<"#
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MIPP,T]X($G1NB.18"KD\<R0WG#LJ,FWS8;N.KRWV2_V(NYB#)#QP^G]/1=-
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M/)A'2HQ7&(5&/1CGN0G9L.7D*XO]<!AQJW*0A =._TVR[?_9/CZL785KH%(
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M<N"*L6.N7_9'W(5\O7A[R_J;V3/QKO# V='3B?:E_;O\V='_ %!+ 0(4 Q0
M   ( %B! E=XJ#PYX3(  #=7 P >              "  0    !E>&AI8FET
M.3DQ+65A<FYI;F=S<F5L96%S92YH=&U02P$"% ,4    " !8@0)7DA9":(P0
M  "K.P  '@              @ $=,P  97AH:6)I=#DY,BUP<F5S<W)E;&5A
M<V5X,#@N:'1M4$L! A0#%     @ 6($"5YK:OO%%$   2C<  !X
M     ( !Y4,  &5X:&EB:70Y.3,M<')E<W-R96QE87-E># X+FAT;5!+ 0(4
M Q0    ( %B! E=[7MBN0A,  -B&   1              "  694  !P86-B
M+3(P,C,P.# R+FAT;5!+ 0(4 Q0    ( %B! E>5UE+!>0(  )L'   1
M          "  ==G  !P86-B+3(P,C,P.# R+GAS9%!+ 0(4 Q0    ( %B!
M E??AADK30H  !I=   5              "  7]J  !P86-B+3(P,C,P.# R
M7VQA8BYX;6Q02P$"% ,4    " !8@0)7:?YR@+,&  #^,   %0
M    @ '_=   <&%C8BTR,#(S,#@P,E]P<F4N>&UL4$L%!@     '  < Z $
' .5[      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
